Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
20-23 October, 2025
62nd Japanese Peptide62nd Japanese Peptide
Not Confirmed
Not Confirmed
21-23 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
20-23 October, 2025
62nd Japanese Peptide62nd Japanese Peptide
Industry Trade Show
Not Confirmed
21-23 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-re-expanding-our-cdmo-capabilities-to-meet-the-next-wave-of-complex-therapies-starting-with-oncology
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india
15 May 2025
// PRESS RELEASE
https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld/
28 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250428674777/en/Boston-Pharmaceuticals-to-Present-the-Effect-of-Efimosfermin-Alfa-on-Collagen-Biomarkers-in-Patients-with-F2-and-F3-MASH-at-EASL-Congress-2025
23 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250423472313/en/Boston-Pharmaceuticals-to-Present-State-of-the-Art-Lecture-and-Poster-for-Once-monthly-Efimosfermin-Alfa-at-Digestive-Disease-Week-2025
15 Nov 2024
// BUSINESSWIRE
16 Oct 2024
// BUSINESSWIRE
06 Jun 2024
// BUSINESSWIRE
ABOUT THIS PAGE